Faculty profile

Rémi Rabasa-Lhoret

ResearcherUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.

Rémi Rabasa-Lhoret

Researcher

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
10 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2024.
Supervisor on 8 trainee awards (8 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Type 1 Diabetes Hypoglycemia Closed-Loop System Glucagon Insulin Physical Activity Artificial Pancreas Carbohydrates

Latest papers

Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD).
Hormone research in paediatrics · 2026
Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?
Diabetes care · 2025

All 27 publications

Latest funding

A randomized controlled trial of Functional mobiLity and resistance EXercise for postmenopausal females with type 1 diabetes: The FLEX-T1D trial
CIHR · 2026 · Co-investigator
$745,875
Feasibility and adoption of an early-stage screening program for relatives of individuals with type 1 diabetes in Canada - The FEDERATE-Can study
CIHR · 2025 · Supervisor
$120,000
Updating pReventive and treatment guidelinEs for Mild hypOglycemia in individuals with Type 1 diabetes During the Era of continuous gLucose monitoring: The REMODAL trial
CIHR · 2024 · Nominated PI
$416,924

All 19 grants and awards

27 publications.

Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines.

Talbo MK, Peters TM, Yale JF, Katz A, Laforest C, Vanasse A, Kichler JC, Rabasa-Lhoret R, Brazeau AS

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026

DOI: 10.1016/j.eprac.2026.01.004 PMID: 41547387

The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD).

Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, Danne T, Davis EA, Dovc K, Forlenza GP, Gillard P, Hofer SE, Hovorka R, Jacobs PJ, Mader JK, Mathieu C, Nørgaard K, Oliver NS, O'Neal DN, Pemberton J, Rabasa-Lhoret R, Sherr JL, Sourij H, Tauschmann M, Yardley JE, Riddell MC

Hormone research in paediatrics2026

DOI: 10.1159/000542287 PMID: 39657609

Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?

Kugathasan L, Dutta P, Nardone M, Sridhar VS, Campbell DJT, Layton AT, Perkins BA, Barbour S, Lam TKT, Levin A, Lovblom LE, Mucsi I, Rabasa-Lhoret R, Rac VE, Senior P, Sigal RJ, Vukobradovic A, Persson F, Stougaard EB, Doria A, Cherney DZI

Diabetes care2025

DOI: 10.2337/dc24-2840 PMID: 40100966

Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.

Nardone M, Kugathasan L, Sridhar VS, Dutta P, Campbell DJT, Layton AT, Perkins BA, Barbour S, Lam TKT, Levin A, Lovblom LE, Mucsi I, Rabasa-Lhoret R, Rac VE, Senior P, Sigal RJ, Stanimirovic A, Persson F, Stougaard EB, Doria A, Cherney DZI

Clinical journal of the American Society of Nephrology : CJASN2025

DOI: 10.2215/cjn.0000000641 PMID: 39918875

Characteristics associated with having a hemoglobin A1c ≤ 7 % (≤53 mmol/mol) among adults with type 1 diabetes using an automated insulin delivery system.

Wu Z, Talbo M, Lebbar M, Messier V, Courchesne A, Brazeau AS, Rabasa-Lhoret R

Diabetes research and clinical practice2023Senior author

DOI: 10.1016/j.diabres.2023.111006 PMID: 37952601

Gender differences in reported frequency and consequences of hypoglycemia among adults living with type 1 diabetes: Results from the BETTER registry.

Talbo MK, Lebbar M, Wu Z, Vanasse A, Lalanne-Mistrih ML, Brazeau AS, Rabasa-Lhoret R

Diabetes research and clinical practice2023Senior author

DOI: 10.1016/j.diabres.2023.110822 PMID: 37423499

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.

Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S, Ismail HM, Kelly A, Moran AM, Rabasa-Lhoret R, Saxby NA, Craig ME

Pediatric diabetes2022

DOI: 10.1111/pedi.13453 PMID: 36537525

Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.

Del Bianco-Rondeau M, Robert-Halabi M, Bloom S, Rabasa-Lhoret R, Tardif JC, Lordkipanidzé M, Marquis-Gravel G

Thrombosis and haemostasis2022

DOI: 10.1055/s-0042-1743469 PMID: 35253137

Gender Differences in Strategies to Prevent Physical Activity-Related Hypoglycemia in Patients With Type 1 Diabetes: A BETTER Study.

Prévost MS, Rabasa-Lhoret R, Talbo MK, Yardley JE, Curry EG, Brazeau AS

Diabetes care2022

DOI: 10.2337/dc21-1899 PMID: 35045175

Can continuous glucose monitoring technology reduce fear of hypoglycemia in people with type 1 diabetes?

Talbo MK, Peters T, Brazeau AS, Rabasa-Lhoret R, Yale JF

Polish archives of internal medicine2022

DOI: 10.20452/pamw.16209 PMID: 35226443

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Type 1 Diabetes Dear Professor Rabasa-Lhoret, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Updating pReventive and treatment guidelinEs for Mild hypOglycemia in individuals with Type 1 diabetes During the Era of continuous gLucose monitoring: The REMODAL trial" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Rémi Rabasa-Lhoret

Research

Latest papers

Latest funding

Screening for Fear of Hypoglycemia in Type 1 Diabetes: Aligning Clinical Practice With Current Guidelines.

The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD).

Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?

Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.

Characteristics associated with having a hemoglobin A1c&#xa0;&#x2264;&#xa0;7&#xa0;% (&#x2264;53&#xa0;mmol/mol) among adults with type 1 diabetes using an automated insulin delivery system.

Gender differences in reported frequency and consequences of hypoglycemia among adults living with type 1 diabetes: Results from the BETTER registry.

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.

Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.

Gender Differences in Strategies to Prevent Physical Activity-Related Hypoglycemia in Patients With Type 1 Diabetes: A BETTER Study.

Can continuous glucose monitoring technology reduce fear of hypoglycemia in people with type 1 diabetes?

Frequent collaborators

Rémi Rabasa-Lhoret

Anne-Sophie Brazeau

Anne-Sophie Brazeau

Peter Senior

May Faraj

May Faraj

Denis Prud'homme

Istvan Mucsi

Ahmad Haidar

Sean Barbour

Adeera Levin

Aleksandra Vukobradovic

Mary-Ellen Harper

Kate Farnsworth

Bruce Perkins

Emmanuelle Brochiero

Laurent Legault

Laurent Legault

Éric Doucet

Tricia Peters

Peter Senior

Kristi Adamo

Emile Levy

Jean-Claude Tardif

Jean-Claude Tardif

Characteristics associated with having a hemoglobin A1c ≤ 7 % (≤53 mmol/mol) among adults with type 1 diabetes using an automated insulin delivery system.